Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement
Authors:
- Clifford W. ColwellCCClifford W. Colwell
- Charles W. FrancisCFCharles W. Francis
- Jeffrey S. GinsbergJGJeffrey S. Ginsberg
- Scott D. BerkowitzSBScott D. Berkowitz
- James WhippleJWJames Whipple
- Gary PetersGPGary Peters
Open Access
- 8 October 2001
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 161 (18) , 2215-2221
Abstract
VENOUS thromboembolism is a common complication after total knee replacement surgery. In the absence of prophylaxis, approximately 60% of patients have venographic evidence of deep vein thrombosis at hospital discharge.1 Although prophylaxis with low-molecular-weight heparin is effective and safe, approximately 30% of patients still develop deep vein thrombosis.2-5 Most of these thrombi are small, asymptomatic, and confined to the deep veins of the calf. However, the prevalence of proximal (eg, popliteal or more proximal) deep vein thrombosis, which is most frequently associated with symptomatic venous thromboembolism and fatal pulmonary embolism, is still approximately 6%,5 possibly because heparins are poor inhibitors of clot-bound thrombin.6 Moreover, low-molecular-weight heparin currently must be given by subcutaneous injection, which is inconvenient for some patients. Although oral warfarin sodium prophylaxis is convenient, frequent laboratory monitoring and dose adjustment are required, and warfarin is not as effective as low-molecular-weight heparin.3-5 Clearly, more effective and convenient prophylaxis is needed. Recently, prophylaxis with a direct thrombin inhibitor (recombinant desulfato-hirudin or desirudin), which potently inhibits clot-bound thrombin, was shown to be significantly more effective than and as safe as low-molecular-weight heparin after total hip replacement.7 However, the first dose was given immediately after spinal anesthesia and before surgery, which might increase the risk for operative bleeding and formation of spinal hematomas.8 In addition, desirudin has not been studied as prophylaxis for total knee replacement; it also must be given as a subcutaneous injection, which potentially limits its convenience.Keywords
This publication has 9 references indexed in Scilit:
- A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip ReplacementNew England Journal of Medicine, 1997
- Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*Journal of Bone and Joint Surgery, 1997
- Prevention of venous thromboembolism after knee arthroplasty: A randomized, double blind trial comparing enoxaparin with warfarinTransfusion Medicine Reviews, 1996
- Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393The Lancet, 1996
- Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.Circulation, 1994
- RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.Journal of Bone and Joint Surgery, 1994
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Pulmonary Angiography, Ventilation Lung Scanning, and Venography for Clinically Suspected Pulmonary Embolism with Abnormal Perfusion Lung ScanAnnals of Internal Medicine, 1983
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972